ImmLab has developed novel technological inventions for the prevention and treatment of infections caused by Staphylococcus aureus in humans and animals. The company’s patented technology of Staphylococcal-lysate-based vaccines allows further development of new products in reaction to actual epidemiological situations resulting from emerging, resistant bacterial strains. All of ImmLab´s intellectual property, technology, and vaccine strains are patented. All microbial strains used for the manufacturing of the products are deposited in international collections according to the Budapest treaty.
ImmLab has been granted multiple Patents from the United States Patent and Trademark Office for its “Compositions and Methods for Treatment of Microbial Infections”. ImmLab has also been granted and issued Patents in Canada,Hong Kong, Japan, and South Korea, as well as granted a European patent, along with individual EU countries of Germany, United Kingdom, France, Czech Republic, and Slovakia.